At a glance
ClinicalIndex Comparison Record- ✓Histologically-confirmed, bi-dimensionally measurable, recurrent or metastatic breast carcinoma that is progressive
- ✓Premenopausal status, defined by recent menstruation, FSH level, or estradiol in premenopausal range
- ✓Estrogen and/or progesterone receptor positive by IHC or competitive binding assay on metastatic or primary tumor
- ✓ECOG performance status 0, 1, or 2
- ✕Active, unresolved infection
- ✕Active malignancy other than breast cancer (except in situ cervical carcinoma or non-melanomatous skin cancers) within past 5 years
- ✕Prior aromatase inhibitor or inactivator treatment
- ✕Prior LHRH agonist/antagonist treatment
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of Arimidex Plus Zoladex in the Treatment of Hormone Receptor Positive, Metastatic Carcinoma of the Breast in Premenopausal Women
In Brief
A Phase 2 clinical trial evaluating Anastrozole (Arimidex) and Goserelin (Zoladex) for Breast Cancer. Completed, enrolled 35 participants across 1 site.
Detailed Summary
To evaluate the antitumor activity, toxicity, and effectiveness of the combination of goserelin (Zoladex) and anastrozole (Arimidex) in the treatment of premenopausal women with hormone receptor positive metastatic carcinoma of the breast.
Study Details
Timeline
Interventions
Anastrozole is a prescription hormonal treatment that helps fight breast cancer by lowering the amount of estrogen in the body. It is a non-steroidal aromatase inhibitor, which significantly lowers serum estradiol (estrogen) concentrations, without interfering with the formation of adrenal corticosteroids or aldosterone
Goserelin is a palliative treatment of advanced breast cancer in pre- and perimenopausal women